TABLE 2.
Unweighted and weighted replication cohort patient characteristics stratified by immunosuppressant (IS) exposure and leukocyte telomere length (LTL) group
| Replication cohort | Weighted replication cohort | ||||||
| IS exposed (n=105) | IS unexposed (n=220) | p-value | IS exposed (n=112) | IS unexposed (n=217) | p-value | SMD | |
| Cohort | <0.01 | 0.24 | 0.28 | ||||
| UTSW | |||||||
| UCSF | 50 (48) | 120 (55) | 74 (66) | 117 (54) | |||
| Chicago | 14 (13) | 56 (26) | 14 (13) | 47 (22) | |||
| UCD | 41 (39) | 44 (20) | 24 (21) | 53 (24) | |||
| CUMC | |||||||
| ILD diagnosis | <0.01 | 0.70 | 0.13 | ||||
| fHP | 49 (47) | 77 (35) | 36 (32) | 84 (39) | |||
| CTD-ILD# | 18 (17) | 18 (8) | 14 (13) | 22 (10) | |||
| uILD | 38 (36) | 125 (57) | 62 (56) | 111 (51) | |||
| Age, years | 63±12 | 69±10 | <0.01 | 68±11 | 67±11 | 0.58 | 0.11 |
| Male | 49 (47) | 110 (50) | 0.66 | 54 (48) | 105 (49) | 0.98 | 0.01 |
| Ethnicity/race | 0.08 | 0.86 | 0.03 | ||||
| White | 59 (56) | 143 (65) | 73 (65) | 137 (63) | |||
| African American | 20 (19) | 41 (19) | 17 (15) | 37 (17) | |||
| Hispanic | 16 (15) | 19 (9) | 12 (11) | 24 (11) | |||
| Asian | 6 (6) | 14 (6) | 8 (7) | 16 (8) | |||
| Other¶ | 4 (4) | 3 (2) | 3 (3) | 3 (1) | |||
| Ever-smoker | 46 (44) | 134 (61) | 0.01 | 73 (65) | 125 (57) | 0.51 | 0.11 |
| Family history of ILD | 13 (12) | 15 (7) | 0.14 | 11 (10) | 20 (9) | 0.84 | 0.04 |
| Lung function | |||||||
| FVC % pred | 65±16 | 71±21 | <0.01 | 72±16 | 70±20 | 0.50 | 0.11 |
| DLCO % pred | 50±19 | 51±21 | 0.62 | 50±17 | 50±21 | 0.85 | 0.03 |
| Radiographic UIP | |||||||
| UIP+ | 8 (8) | 38 (17) | 0.03 | 10 (9) | 30 (14) | 0.41 | 0.12 |
| Honeycombing | 22 (21) | 56 (25) | 0.45 | 21 (19) | 45 (21) | 0.77 | 0.05 |
| IS therapy | |||||||
| Mycophenolate | 91 (87) | 99 (89) | |||||
| Azathioprine | 14 (13) | 13 (11) | |||||
| IS exposure, years | 1.5 (0.5–2.0) | 1.7 (0.8–2.0) | |||||
| Prednisone | 87 (83) | 70 (32) | <0.01 | 50 (44) | 103 (48) | 0.72 | 0.07 |
| LTL | |||||||
| LTL <10th percentile | 21 (20) | 63 (29) | 0.13 | 26 (24) | 62 (29) | 0.61 | 0.12 |
| Age-adjusted LTL | 0.2 (−0.3–0.6) | 0.1 (−0.4–0.5) | 0.12 | 0.1 (−0.3–0.4) | 0.1 (−0.4–0.5) | 0.75 | 0.03 |
| Follow-up, years | 2.0 (2.0–2.0) | 2.0 (1.1–2.0) | 0.03 | 2.0 (2.0–2.0) | 2.0 (1.4–2.0) | 0.34 | 0.23 |
| Outcome | |||||||
| Death within 2 years | 17 (16) | 42 (19) | 0.63 | 21 (19) | 39 (18) | 0.95 | 0.01 |
| Transplant within 2 years | 1 (1) | 3 (1) | 1.0 | 1 (1) | 2 (1) | 0.40 | 0.07 |
Data are presented as n (%), mean±sd or median (interquartile range). SMD: standardised mean difference; UTSW: University of Texas Southwestern; UCSF: University of California San Francisco; Chicago: University of Chicago; UCD: University of California Davis; CUMC: Columbia University Medical Center; ILD: interstitial lung disease; fHP: fibrotic hypersensitivity pneumonitis; CTD: connective tissue disease; uILD: unclassifiable ILD; FVC: forced vital capacity: DLCO: diffusing capacity of the lung for carbon monoxide; UIP: usual interstitial pneumonia. #: CTD-ILD diagnoses: scleroderma n=19, rheumatoid arthritis n=5, inflammatory myositis n=6, mixed CTD n=1, Sjögren's syndrome n=2, systemic lupus erythematosus n=3; ¶: other ethnicity/race: Middle Eastern n=2, Native American n=2, Pacific Islander n=3; +: radiographic UIP incudes definite UIP.